The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Julio DelgadoDuring the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak with Julio Delgado, Hospital Clínic de Barcelona, Barcelona, ES. We asked, How might CAR T-cells change the treatment landscape for patients with chronic lymphocytic leukemia (CLL)?
How might CAR T-cells change the treatment landscape for patients with CLL?
Delgado begins by outlining the recent improvements in CLL treatment, including new drug approvals (such as BTK and BCL-2 inhibitors). On the other hand, there are also patients (e.g., those with high-risk cytogenetics or for whom other therapies have failed) who are being referred for CAR-T therapy. However, Delgado highlights that there are no CAR-T cell products approved in the EU, meaning patients need to be enrolled in trials. Finally, Delgado gives his recommendations on treatment choices for high-risk CLL.